Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor

被引:127
作者
Yang, Syaulan
Chen, Shu-Jen
Hsu, Min-Feng
Wu, Jen-Dar
Tseng, Chien-Te K.
Liu, Yu-Fan
Chen, Hua-Chien
Kuo, Chun-Wei
Wu, Chi-Shen
Chang, Li-Wen
Chen, Wen-Chang
Liao, Shao-Ying
Chang, Teng-Yuan
Hung, Hsin-Hui
Shr, Hui-Lin
Liu, Cheng-Yuan
Huang, Yu-An
Chang, Ling-Yin
Hsu, Jen-Chi
Peters, Clarence J. [1 ]
Wang, Andrew H. -J.
Hsu, Ming-Chu
机构
[1] TaiGen Biotechnol Co, Taipei 114, Taiwan
[2] Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan
[3] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan
[4] Acad Sinica, Core Facil Prot Xray Crystallog, Taipei 115, Taiwan
[5] Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA
关键词
D O I
10.1021/jm0603926
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG- 0205221, K-i = 53 nM) has been developed. TG- 0205221 showed remarkable activity against SARS CoV and human coronavirus ( HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 mu M) for SARS CoV and 5.2 log (at 1.25 mu M) for HCoV 229E. The crystal structure of TG- 0205221 (resolution = 1.93 angstrom) has revealed a unique binding mode comprising a covalent bond, hydrogen bonds, and numerous hydrophobic interactions. Structural comparisons between TG- 0205221 and a natural peptide substrate were also discussed. This information may be applied toward the design of other 3CL protease inhibitors.
引用
收藏
页码:4971 / 4980
页数:10
相关论文
共 24 条
[1]   Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].
Anand, K ;
Ziebuhr, J ;
Wadhwani, P ;
Mesters, JR ;
Hilgenfeld, R .
SCIENCE, 2003, 300 (5626) :1763-1767
[2]  
[Anonymous], ACTA CRYSTALLOGR D
[3]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]   Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors.: 4.: Incorporation of P1 lactam moieties as L-glutamine replacements [J].
Dragovich, PS ;
Prins, TJ ;
Zhou, R ;
Webber, SE ;
Marakovits, JT ;
Fuhrman, SA ;
Patick, AK ;
Matthews, DA ;
Lee, CA ;
Ford, CE ;
Burke, BJ ;
Rejto, PA ;
Hendrickson, TF ;
Tuntland, T ;
Brown, EL ;
Meador, JW ;
Ferre, RA ;
Harr, JEV ;
Kosa, MB ;
Worland, ST .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) :1213-1224
[6]  
DRAGOVICH PS, 2003, Patent No. 6531452
[7]   Identification of a novel coronavirus in patients with severe acute respiratory syndrome [J].
Drosten, C ;
Günther, S ;
Preiser, W ;
van der Werf, S ;
Brodt, HR ;
Becker, S ;
Rabenau, H ;
Panning, M ;
Kolesnikova, L ;
Fouchier, RAM ;
Berger, A ;
Burguière, AM ;
Cinatl, J ;
Eickmann, M ;
Escriou, N ;
Grywna, K ;
Kramme, S ;
Manuguerra, JC ;
Müller, S ;
Rickerts, V ;
Stürmer, M ;
Vieth, S ;
Klenk, HD ;
Osterhaus, ADME ;
Schmitz, H ;
Doerr, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1967-1976
[8]   Aetiology -: Koch's postulates fulfilled for SARS virus [J].
Fouchier, RAM ;
Kuiken, T ;
Schutten, M ;
van Amerongen, G ;
van Doornum, J ;
van den Hoogen, BG ;
Peiris, M ;
Lim, W ;
Stöhr, K ;
Osterhaus, ADME .
NATURE, 2003, 423 (6937) :240-240
[9]   Mechanism of the maturation process of SARS-CoV 3CL protease [J].
Hsu, MF ;
Kuo, CJ ;
Chang, KT ;
Chang, HC ;
Chou, CC ;
Ko, TP ;
Shr, HL ;
Chang, GG ;
Wang, AHJ ;
Liang, PH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) :31257-31266
[10]   Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers [J].
Hsyu, PH ;
Pithavala, YK ;
Gersten, M ;
Penning, CA ;
Kerr, BM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :392-397